Product sheet

[redacted]HK-CRISPR-Nup188-mEGFP | 300657

[redacted]

Description	HK-CRISPR-Nup188-mEGFP [redacted] Hela Kyoto [redacted]. [redacted] CRISPR/Cas9 [redacted] mEGFP Nup188, [redacted] [redacted]
Organism	[redacted]
Tissue	[redacted]
Disease	[redacted]
Metastatic site	Not applicable (HeLa Kyoto derivative; primary tumor site is endocervix)
Applications	Nuclear pore complex (NPC) biology; nucleocytoplasmic transport; Nup188 dynamics and function; live-cell fluorescence imaging of nuclear envelope; high-content screening; CRISPR knock-in validation studies; nuclear transport inhibitor evaluation

[redacted]

Age	30 [redacted]
Gender	[redacted]
Ethnicity	[redacted]
Morphology	[redacted]
Cell type	Epithelial cells
Growth properties	[redacted]

[redacted]

Citation	HK-CRISPR-Nup188-mEGFP ([redacted] Cytion 300657)
Biosafety level	1

[redacted]HK-CRISPR-Nup188-mEGFP | 300657

NCBI_TaxID	9606
CellosaurusAccession	Not assigned (HK-CRISPR-Nup188-mEGFP is a CRISPR-modified HeLa Kyoto derivative; parental HeLa Kyoto CVCL_1922)
Depositor	[redacted] (EMBL)
GMO Status	GMO-S1: [redacted] HeLa Kyoto [redacted] CRISPR knock-in [redacted] mEGFP [redacted] Nup188, [redacted]

[redacted]

Protein expression	Nup188, mEGFP-tag

[redacted]

Culture Medium	DMEM, w: 4.5 g/L [redacted], w: 4 mM L-[redacted], w: 3.7 g/L NaHCO3, w: 1.0 mM [redacted] (Cytion 820300a)
Supplements	[redacted] 10% FBS
Dissociation Reagent	[redacted]
Subculturing	[redacted] PBS [redacted] T25, [redacted] 3 [redacted]
Freeze medium	[redacted] (FBS) + 10% DMSO [redacted]

[redacted]HK-CRISPR-Nup188-mEGFP | 300657

Thawing and Culturing Cells	1. [redacted] 2. [redacted] 3. [redacted] 4. [redacted] 5. [redacted] 6. [redacted] 7. [redacted] 8. [redacted]
Incubation Atmosphere	37°C, 5% $_{CO2}$, [redacted]
Flask Coating	[redacted]
Freezing Procedure	[redacted]
Shipping Conditions	[redacted]
Storage Conditions	[redacted]

[redacted] / [redacted] / HLA

Sterility	[redacted] [redacted]